Health knowledge made personal
Join this community!
› Share page:
Search posts:

Method of Inducing Memory B Cell Development and Terminal Differentiation

Posted Apr 30 2008 5:00pm

Description of Invention:
Cytokines exert their respective biochemical and physiological effects by binding to specific receptor molecules, which then stimulate signal transduction pathways. Interleukin-21 (IL-21) is a type I cytokine whose receptor is expressed on T, B, and NK cells.

This invention specifically relates to the use of IL-21 to induce differentiation of immature B cells into memory B cells and plasma cells. This invention includes claims of methods for inducing differentiation of a B cell progenitor into memory B cells and/or plasma cells. It also includes claims for enhancing an immune response, treating subjects that lack memory B cells and plasma cells and methods for increasing or decreasing the number of B cells. This invention could conceivably be used in treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Peter E Lipsky (NIAMS)

Patent Status:
HHS, Reference No. E-120-2003/2
US, , Patent No. 7,378,276, Issued 27 May 2008
US, Application No. 12/126,166 filed 23 May 2008

Cancer - Therapeutics
Internal Medicine
Internal Medicine - Diagnostics
Internal Medicine - Therapeutics

For Additional Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-4633
Fax: 301-402-0220

Ref No: 1338

Updated: 05/2008

Post a comment
Write a comment: